What Is Viridian Therapeutics, Inc. (VRDN) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Viridian Therapeutics, Inc.'s intrinsic value is estimated at $6.20. Trading at its current price of $19.06, the valuation engine raises significant caution: 8 of 9 models flag downside risk, projecting an average implied return of -67.5%. Model dispersion is worth noting: PWERM targets $20.18 (+5.9%), versus ML-RIV at $0.41 (-97.9%). This +103.8% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About VRDN?
9 of 13 models are currently active for VRDN. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates VRDN's intrinsic value at $6.82, implying -64.2% downside from the current price. See which stocks rank higher →
How Does VRDN Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, VRDN ranks #138 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Viridian Therapeutics, Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.
Is VRDN a Value Trap?
CirclFi's Value Trap algorithm assigns VRDN a score of 28/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Viridian Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Viridian Therapeutics, Inc. scores 5.9 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +103.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every VRDN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across VRDN's 9 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad